Collection
Curated by Dr. Roshni Dasgupta From 3 sources across the library

Hepatobiliary & Pancreatic Oncology

items total cited expert statements Updated Oct 30, 2026
Start exploring
Try
Intelligent Search· answers come only from this collection · not medical advice
Content of this collection items

R0 resection is associated with decreased expected hazards of experiencing an event (hazard ratio 0.14, 95% confidence interval 0.05-0.38) in multivariate analysis. Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study

Hepatocellular Neoplasms1 item
Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study
Hepatocellular carcinoma (HCC) is a rare cancer in children, with various histologic subtypes and a paucity of data to guide clinical management and predict prognosis. A multi-institutional review of children with hepatocellular neoplasms w
article · Oct 2026
Read →
Hepatoblastoma1 item
Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
Stephanie F Polites, Jennifer H Aldrink, Timothy B Lautz, Robert A Vierkant, Mecklin V Ragan, Audra Reiter, Stephanie Y Chen, Eugene S Kim, Hannah N Rinehardt, Marcus M Malek, Andrew M Fleming, Andrew J Murphy, Jonathan P Roach, Sridharan R
video1:10 · Apr 2026
Watch →
Undifferentiated Embryonal Sarcoma1 item
Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare tumor for which there are few evidence-based guidelines. The aim of this study was to define current management strategies and outcomes for these patients using a
article · Oct 2026
Read →

Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study
This is the largest series of pediatric PD patients. PD is curative for SPN and benign neoplasms. Pancreatic insufficiency is the most common postoperative complication. Outcome is primarily associated with histology.
article · Oct 2026
Read →

Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
It is not uncommon for a patient with hepatoblastoma to need a transfusion during resection
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:00
The study was multi-institutional and published in Pediatric Blood and Cancer in 2025
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:13
The study examined how intraoperative transfusion may affect recurrence and survival in hepatoblastoma resection patients
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:19
Of those transfused, the majority received red blood cells
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:25
Only 11% of transfused patients received platelets
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:25
Intraoperative blood transfusions had no effect on recurrence
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:32
Intraoperative blood transfusions were associated with increased death
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:32
There were instances of unnecessary blood transfusions
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:39
Patients who were transfused had higher post-op hemoglobin
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:43
Transfused patients still required more plasma and platelets postoperatively
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:43
The authors think that blood transfusions were mostly red blood cells, and that is what contributed to the post-op coagulopathy
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:52
The authors recommend more careful patient selection for intraoperative transfusions
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position1:00
The authors recommend a balanced transfusion approach
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position1:00
Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
The median age at presentation for undifferentiated embryonal sarcoma of the liver is 9.9 years (interquartile range 7-12 years).
Cites published research
Twenty-seven patients (35%) underwent resection at diagnosis while 47 patients (60%) underwent delayed resection after neoadjuvant chemotherapy.
Cites published research
Eight patients underwent liver transplantation as part of their surgical management.
Cites published research
Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm (interquartile range 0.0-4.4 cm).
Cites published research
Greater than 90% tumor necrosis was achieved in 79% of patients undergoing delayed resection after neoadjuvant chemotherapy.
Cites published research
R0 resections were accomplished in 63 patients (81% of the cohort).
Cites published research
Metastatic disease at presentation impacts overall survival in univariate analysis.
Cites published research
Completeness of resection impacts both event-free survival and overall survival in univariate analysis.
Cites published research
R0 resection is associated with decreased expected hazards of experiencing an event (hazard ratio 0.14, 95% confidence interval 0.05-0.38) in multivariate analysis.
Cites published research
GCMD Library — Curated collection · summaries prepared automatically from the recordings · educational content, not medical advice
Start the course
We remember your choice for this collection.
Follow this collection We'll email you when something new is added to Hepatobiliary & Pancreatic Oncology — the new recordings themselves, with links. Nothing when nothing is added; every email has an unsubscribe link.